Smart: A phase ii study of sacituzumab govitecan (sg) with or without atezolizumab immunotherapy in rare genitourinary (gu) tumors such as small cell, adenocarcinoma, and squamous cell bladder/urinary tract cancer, renal medullary carcinoma (rmc) and penile cancer - Kydd, AR; Chandran, E; Simon, NI (Journal of Clinical Oncology, 2024)